3001 Red Lion Road
+1 215 501 1210
PCI Pharma Services, Excellence in Pharmaceutical Outsourcing, from Molecule to Market
PCI Pharma Services is an integrated full service provider, a proven and trusted partner to leading companies in the global healthcare industry. We offer unparalleled expertise and experience in taking compounds from the earliest stages of development through to successful commercialisation, delivering speed-to-market and commercial success for our customers.
Our core services support each stage of the product lifecycle, including drug development, clinical trial supply, commercial launch and ongoing commercial supply. We partner with clients in providing innovative technologies, flexible solutions, and an integrated supply network supporting lifesaving medicines destined to over 100 countries around the world.
We support clients with a dedication to providing the industry’s leading experience, exemplified in our operational flexibility, delivery, commitment to safety, supported by industry leading technologies and an exemplary quality and regulatory record. This has allowed us to be the partner of choice for leading pharmaceutical companies around the world, operating as a seamless extension of their business.
Following the acquisition of Penn Pharma, our comprehensive service offering includes early stage formulation and analytical development, drug in capsule/vial using Xcelodose technology, scale-up and stability testing, process validation, technology transfer and all associated analytical support services.
PCI offers a broad range of services to address the manufacturing needs of our clients at each stage of the product lifecycle. Central to PCI’s international service offering is our capability to manufacture a range of dosage forms in compliance with current GMP standards.
PCI offers flexible and globally compliant commercial scale manufacturing of tablets, capsules, semi-solid and liquid oral preparations. Recent investments include separate suites for large volume tablet manufacture and dry granulation for moisture sensitive formulations. Our aim is to provide a comprehensive service from launch through to worldwide supply from an experienced production team supported by engineering and validation specialists.
With significant experience of providing clinical packaging and labelling services, PCI combines knowledge, experience, and innovative technologies that ensure we can supply products reliably and effectively wherever in the world our clients need them.
PCI is able to offer packaging solutions for unique products, with segregated suites and facilities for those products requiring special handling including Potent Packaging, Cold Chain, Biologics and Advanced Therapeutic Medicinal Products (ATMPs).
PCI is a leader in the commercialisation of new medicines by meeting the varying needs of each customer and each market we serve. Our insights and expertise help provide Package Design and Development and solutions to differentiate products in crowded and competitive markets, delivering product to patients creatively and effectively.
PCI features fully audited, in-house laboratories in both our European and North America locations offering a range of analytical services to support clients in the development and commercialisation of new medicines.
Qualified Persons (QPs) play a vital role in bringing products to market within Europe. Global clients look to the diverse range of skills and specialisms of our highly experienced team of QPs to ensure their clinical studies not only meet the most rigorous standards but also run smoothly, seamlessly and cost effectively.
PCI offers the experience and insights of over 30 years in the storage and distribution of clinical trial materials, effectively storing and shipping thousands of patient kits to over 100 existing and emerging clinical trial countries across the world.
#SaveTheDate and Join us at our Good Morning Meeting— PCI Pharma Services (@PCI_Social) May 21, 2018
June 6th | 7.30am - Intercontinental Boston Waterfront Hotel
Find out about expediting your #Phase1ClinicalTrials in Australia ðŸ‡¦ðŸ‡ºðŸ‡¦ðŸ‡ºðŸ‡¦ðŸ‡º@InterConBOS pic.twitter.com/0HQZGOQohu
High Potent Medicine Conference 2018— PCI Pharma Services (@PCI_Social) May 20, 2018
David O'Connell, our Director of Scientific Affairs, will be discussing;
âœ…On-boarding High Potent API's
âœ…The Complexities of the Clinical Phases
âœ…Guiding your High Potent API
Get me more here: https://t.co/HhTnWfdFw0